Neurological disorder

Intranasal Delivery of shRNA Edits to Silence 5-HT2A Receptor Shows Promise in Enhancing Memory and Alleviating Anxiety

Retrieved on: 
Thursday, March 21, 2024
Science, Biotechnology, Research, Pharmaceutical, Health, Mental Health, Genetics, Clinical Trials, Depression, Brain, Dementia, Rat, BBB, Memory, Central nervous system, Public, RNA, Mouse, Traffic barrier, Anxiety, Translational Psychiatry, MCI, Neurological disorder, DSM-IV codes, HTR2A, Intrinsic termination, Therapy, Optimism, Cas9, Vaccine

In a groundbreaking study, they successfully used a non-invasive intranasal delivery platform to administer short-hairpin RNA (shRNA) that targets the 5-HT2A receptor resulting in long-lasting improvements in memory and reduced anxiety in animal models.

Key Points: 
  • In a groundbreaking study, they successfully used a non-invasive intranasal delivery platform to administer short-hairpin RNA (shRNA) that targets the 5-HT2A receptor resulting in long-lasting improvements in memory and reduced anxiety in animal models.
  • Neurological disorders such as Mild Cognitive Impairment (MCI), depression, and anxiety disorders pose significant challenges to public health worldwide.
  • In this study, the researchers designed shRNA sequences to specifically target and silence the human HTR2A gene, which is associated with anxiety and memory.
  • The ability to bypass the blood-brain barrier using intranasal delivery opens up new avenues for precision-based therapeutics in neurological disorders."

FDA Approves Nonsteroidal Treatment for Duchenne Muscular Dystrophy

Retrieved on: 
Thursday, March 21, 2024
Research, HDAC, Neurological disorder, Walking, Abdominal pain, Dietary supplement, Risk, Inflammation, Patient, QT interval, Public, Animal, Duchenne muscular dystrophy, Diarrhea, Food, Human services, Platelet, Facial muscles, Life expectancy, Heated tobacco product, Fever, Atrophy, Safety, Division, NSAA, Muscle weakness, Cosmetics, Vaccine, Multimedia, FDA, DMD, Muscular dystrophy, Triglyceride, Pharmaceutical industry

SILVER SPRING, Md., March 21, 2024 /PRNewswire/ -- Today, the U.S. Food and Drug Administration approved Duvyzat (givinostat) oral medication for the treatment of Duchenne Muscular Dystrophy (DMD) in patients six years of age and older.

Key Points: 
  • SILVER SPRING, Md., March 21, 2024 /PRNewswire/ -- Today, the U.S. Food and Drug Administration approved Duvyzat (givinostat) oral medication for the treatment of Duchenne Muscular Dystrophy (DMD) in patients six years of age and older.
  • Duvyzat is the first nonsteroidal drug approved to treat patients with all genetic variants of DMD.
  • "This approval provides another treatment option to help reduce the burden of this progressive, devastating disease for individuals impacted by DMD regardless of genetic mutation."
  • DMD is the most common childhood form of muscular dystrophy and typically affects males.

Digital Health in the Neurology Market worth $167.58 Bn by 2031 - Exclusive Report by InsightAce Analytic Pvt. Ltd.

Retrieved on: 
Tuesday, March 19, 2024
Health, Brain, Growth, Neurology, Multiple sclerosis, Deficit spending, Seizure, Rehabilitation, Partnership, Patient, Kernel, Internet, Research, Artificial intelligence, Acquisition, Parkinson's disease, Low back pain, Biogen, KMDF, Neurological disorder, DSM-IV codes, Intellectual property, Government, Report, Virtual reality, Medicine, Pharmaceutical industry

There are strict regulatory frameworks in place in several locations that affect the digital health sector of neurology.

Key Points: 
  • There are strict regulatory frameworks in place in several locations that affect the digital health sector of neurology.
  • While these rules are essential for protecting patients' health, they can hinder the development and rollout of innovative digital health solutions in neurology.
  • These limitations are expected to limit the expansion of the digital health market in neurology during the next few years.
  • The North American digital health in neurology market is expected to register a large market share in the revenue.

Digital Health in the Neurology Market worth $167.58 Bn by 2031 - Exclusive Report by InsightAce Analytic Pvt. Ltd.

Retrieved on: 
Tuesday, March 19, 2024
Health, Brain, Growth, Neurology, Multiple sclerosis, Deficit spending, Seizure, Rehabilitation, Partnership, Patient, Kernel, Internet, Research, Artificial intelligence, Acquisition, Parkinson's disease, Low back pain, Biogen, KMDF, Neurological disorder, DSM-IV codes, Intellectual property, Government, Report, Virtual reality, Medicine, Pharmaceutical industry

There are strict regulatory frameworks in place in several locations that affect the digital health sector of neurology.

Key Points: 
  • There are strict regulatory frameworks in place in several locations that affect the digital health sector of neurology.
  • While these rules are essential for protecting patients' health, they can hinder the development and rollout of innovative digital health solutions in neurology.
  • These limitations are expected to limit the expansion of the digital health market in neurology during the next few years.
  • The North American digital health in neurology market is expected to register a large market share in the revenue.

ZyVersa Therapeutics Publishes New White Paper Detailing the Role of Inflammasomes and ASC Specks in Neurological Diseases, and Data Supporting Inflammasome ASC Inhibitor IC 100 as a Potential Therapeutic Option

Retrieved on: 
Thursday, February 22, 2024
ASC, Traumatic brain injury, Inflammation, Quality of life, Neurological disorder, Multiple sclerosis, University, Intellectual disability, Therapy, Neurology, Super Meat Boy, Patient, DSM-IV codes, Clinical trial, Inflammasome, IND, DRS, Research, Pharmaceutical industry

A growing body of evidence supports that activation of more than one type of inflammasome contributes to development of common neurological diseases, and that extracellular ASC specks are involved in disease progression.

Key Points: 
  • A growing body of evidence supports that activation of more than one type of inflammasome contributes to development of common neurological diseases, and that extracellular ASC specks are involved in disease progression.
  • The white paper summarizes the preclinical research of leading inflammasome experts, Drs.
  • The white paper then summarizes data from preclinical research led by Drs.
  • Keane, de Rivero Vaccari, and their colleagues currently have research underway in Parkinson’s disease that was funded through a grant with the Michael J.

New Data Demonstrate Sunbird Bio’s APEX Diagnostic Test Accurately Differentiates Key Alzheimer’s Disease Biomarker in Blood

Retrieved on: 
Tuesday, March 5, 2024
Mental Health, Research, Neurology, Clinical Trials, Biotechnology, Health, General Health, Other Science, Science, Traffic barrier, EV, System, Blood, Cerebrospinal fluid, Neurological disorder, AUC, Amplification, Conference, Seminal vesicles, Biomarker, Patient, Dementia, DSM-IV codes, CSF, Disease, Diagnosis, PET, APEX, Brain, Medical imaging

The data will be shared this week in a poster presentation at the AD/PD™ 2024 International Conference on Alzheimer’s and Parkinson’s Disease.

Key Points: 
  • The data will be shared this week in a poster presentation at the AD/PD™ 2024 International Conference on Alzheimer’s and Parkinson’s Disease.
  • “These results provide further evidence that the APEX platform has the potential to offer highly sensitive and accurate Alzheimer’s disease diagnosis equivalent to PET scans from a simple blood draw,” said John McDonough, executive chair and CEO of Sunbird Bio.
  • The APEX Aβ test is a blood-based diagnostic that uniquely detects very low levels of disease-specific proteins in blood with high accuracy.
  • EV-associated Aβ in blood are highly correlative and a direct reflection of Aβ build-up in the brain, a key abnormality in Alzheimer’s disease.

Teva and Jiangsu Nhwa Forge Strategic Partnership to Promote Patient Access to AUSTEDO® in China

Retrieved on: 
Monday, February 26, 2024
FDA, Health, Neurology, Clinical Trials, Pharmaceutical, Biotechnology, Tardive dyskinesia, Chorea, VMAT2, Metabolism, EVP, Deuterium, Annual report, TEVA, Marketing, Teva, Partnership, HD, Quality of life, Food, Schizophrenia, Neurological disorder, DSM-IV codes, Globalization, Neuro, Prevalence, Happy Mood, Face, Anesthesia, Central nervous system disease, Pivot, Tongue, CNS, Psychiatry, Patient, Pain, Disease, Extremities, Research, Pharmaceutical industry

The partnership intends to increase patients’ access to Teva’s AUSTEDO, leveraging Nhwa’s leadership in China’s neuro-psychiatric health sector.

Key Points: 
  • The partnership intends to increase patients’ access to Teva’s AUSTEDO, leveraging Nhwa’s leadership in China’s neuro-psychiatric health sector.
  • “Nhwa has deep neuro-psychiatry expertise and capabilities, from research and development to commercialization,” commented Theodor Wee, General Manager of Teva Greater China.
  • Chorea, one of the most striking physical manifestations of Huntington’s disease, is a neurological disorder that causes involuntary, random muscle movements.
  • Jiangsu Nhwa Pharmaceutical Co., Ltd., founded in 1978, is a leading CNS company in China.

InBrain Pharma Announces the Appointment of Dr Véronique Foutel as CEO

Retrieved on: 
Tuesday, February 27, 2024
Mental Health, Health, Neurology, Other Health, Clinical Trials, Pharmaceutical, Biotechnology, DBV Technologies, Hospital, Pharmacy, CHU, Dopamine, Growth, Neurological disorder, DSM-IV codes, Entrepreneurship, Pharmaceutical industry, Prevalence, Parkinson's disease, Headquarters, Medicine, Patient, Disease, CSO, Brain

InBrain Pharma, a biotech specialized in brain infusion of drugs for neurological disorder management, today announced the appointment of Dr. Véronique Foutel as CEO to drive the next company's development steps.

Key Points: 
  • InBrain Pharma, a biotech specialized in brain infusion of drugs for neurological disorder management, today announced the appointment of Dr. Véronique Foutel as CEO to drive the next company's development steps.
  • Dr. Matthieu Fisichella, co-founder, and current CEO since 2018, will remain highly committed to InBrain Pharma and become Chief Science Officer.
  • ," says Véronique Foutel, CEO of InBrain Pharma.
  • "I am delighted to hand over the reins to Véronique, whose appointment comes at a critical time for InBrain Pharma.

Family Advocates Urge Congress' Support During Inaugural Angelman Syndrome (AS) Congressional Advocacy Day

Retrieved on: 
Thursday, March 7, 2024
Bangladesh Technical Education Board, Angelman syndrome, Food and Drug Administration, NIH, FDA, Quality of life, Food, Neurological disorder, ASF, Hope, Common, Biomarker, Organization, Policy, Legislation, Disease, Congress, Movement, AS, FAST, Research, Partnership, Pharmaceutical industry

WASHINGTON, March 7, 2024 /PRNewswire-PRWeb/ -- The Angelman Syndrome Foundation (ASF) and the Foundation for Angelman Syndrome Therapeutics (FAST) are hosting the inaugural Angelman Syndrome (AS) Congressional Advocacy Day in Washington, D.C.

Key Points: 
  • The Angelman Syndrome Foundation (ASF) and the Foundation for Angelman Syndrome Therapeutics (FAST) are hosting the inaugural Angelman Syndrome (AS) Congressional Advocacy Day in Washington, D.C.
    WASHINGTON, March 7, 2024 /PRNewswire-PRWeb/ -- The Angelman Syndrome Foundation (ASF) and the Foundation for Angelman Syndrome Therapeutics (FAST) are hosting the inaugural Angelman Syndrome (AS) Congressional Advocacy Day in Washington, D.C.
    "As the Angelman syndrome community gathers in Washington, D.C., we emphasize the critical importance of federal funding for research programs," said Amanda Moore, CEO of ASF.
  • This marks a significant day as these two prominent organizations come together to advance legislative and policy priorities for AS.
  • Angelman syndrome is a rare, neurological disorder that occurs in one in 15,000 individuals.
  • Together, with determination and collaboration, we aim to create a future with more smiles and fewer struggles for individuals affected by Angelman syndrome."

Family Advocates Urge Congress' Support During Inaugural Angelman Syndrome (AS) Congressional Advocacy Day

Retrieved on: 
Thursday, March 7, 2024
Bangladesh Technical Education Board, Angelman syndrome, Food and Drug Administration, NIH, FDA, Quality of life, Food, Neurological disorder, ASF, Hope, Common, Biomarker, Organization, Policy, Legislation, Disease, Congress, Movement, AS, FAST, Research, Partnership, Pharmaceutical industry

This marks a significant day as these two prominent organizations come together to advance legislative and policy priorities for AS.

Key Points: 
  • This marks a significant day as these two prominent organizations come together to advance legislative and policy priorities for AS.
  • Angelman syndrome is a rare, neurological disorder that impacts approximately 1:15,000 individuals.
  • Ryan Fischer, COO of FAST highlights the importance of this step for the AS community, stating, "This event marks a historic day for the community, as it is the first ever organized Hill day for Angelman syndrome.
  • Together, with determination and collaboration, we aim to create a future with more smiles and fewer struggles for individuals affected by Angelman syndrome."